abstract: Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, July 28, 2011

abstract: Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.



Markman M.

Source

Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA.

Abstract

Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.